Phase II study of BW-40202, a small interfering RNA (siRNA) therapy targeting complement factor B (CFB), is planned to commence in January 2026. The therapy is also being The post Argo Biopharma secures NMPA clearance for Phase II PNH trial appeared first on Pharmaceutical Business review.